Clinical Selection of Combined Lipid-regulating Drug Therapies

doi:10.3969/j.issn.1007-9572.2016.36.001

Abstract

Abstract: Blood lipid regulating-therapy is an essential management in primary and secondary prevention of cardiovascular disease.Statins remain the cornerstone of modern lipid-regulating therapy.But statins hardly solve all types of dyslipidemia.In order to offer available combined drug therapies and related considerations for clinical practice,this paper summarized the combined therapies of lowing LDL-C and those of improving mixed dyslipidemia,answered the questions about whether application of these therapies could effectively reduce the cardiovascular risks and explored the application prospect of these therapies based on analyzing the population suitable for combined lipid-regulating drug therapies.

Key words: Lipid regulating agents, Polypharmacy, Clinical protocols

摘要： 调脂治疗是心血管疾病一级预防和二级预防的基本措施，他汀类药物仍是目前调脂治疗的基石。但他汀类药物不适用于治疗所有血脂异常类型。本文通过分析联合药物治疗的适用人群，归纳了临床上用于降低低密度脂蛋白胆固醇的联合方案及用于改善混合型血脂异常的联合方案，进一步探讨了联合使用降脂药物的疑虑与前景，旨在为临床工作提供可供选择的联合方案以及相关的注意事项。

关键词: 调脂药, 多种药物疗法, 临床方案

WANG Xin-yue. Clinical Selection of Combined Lipid-regulating Drug Therapies[J]. Chinese General Practice, 2016, 19(36): 4413-4416.

王欣越. 调脂药物联合使用的临床策略选择[J]. 中国全科医学, 2016, 19(36): 4413-4416.

References

［1］中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南［J］.中华心血管病杂志，2007，35（5）：390-419. Committee for the Prevention and Treatment of Dyslipidemia in Chinese Adults.A guide for the prevention and treatment of dyslipidemia in China［J］.Chinese Journal of Cardiology，2007，35（5）：390-419. ［2］CATAPANO A L,GRAHAM I,DE BACKER G,et al.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias:The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology （ESC） and European Atherosclerosis Society （EAS）Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation （EACPR）［J］.Eur Heart J，2016.［Epub ahead of print］. ［3］ SONG P,LI H,JIA S,et al.Serum total cholesterol status among urban residents aged 18 and above in China from 2010 to 2012［J］.Zhonghua Yu Fang Yi Xue Za Zhi,2016,50（3）:208-212. ［4］第二次中国临床血脂控制状况多中心协作研究组.第二次中国临床血脂控制达标率及影响因素多中心协作研究［J］.中华心血管病杂志,2007,35（5）:420-427. The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China.The second multi-center survey of dyslipidemia management in China:goal attainment rate and related factors［J］.Chinese Journal of Cardiology,2007,35（5）:420-427. 10.3760/j.issn:0253-3758.2007.05.004. ［5］KNAPP H H,SCHROTT H,MA P,et al.Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia［J］.Am J Med,2001,110（5）:352-360. ［6］HUNNINGHAKE D,INSULL W J R,TOTH P,et al.Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively［J］.Atherosclerosis,2001,158（2）:407-416. ［7］DAVIDSON M H,BALLANTYNE C M,KERZNER B,et al.Efficacy and safety of ezetimibe coadministered with statins:randomized,placebo-controlled,blinded experience in 2382 patients with primary hypercholesterolemia［J］.Int J Clin Pract,2004,58（8）:746-755. ［8］KASTELEIN J J,AKDIM F,STROES E S,et al.Simvastatin with or without ezetimibe in familial hypercholesterolemia［J］.N Engl J Med,2008,358（14）:1431-1443. ［9］ BAIGENT C,BLAZING M A,KING T R,et al.Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia［J］.Am J Cardiol,2004,93（12）:1487-1494. ［10］CATAPANO A L,DAVIDSON M H,BALLANTYNE C M,et al.Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients［J］.Curr Med Res Opin,2006,22（10）:2041-2053. ［11］ GAGNE C,GAUDET D,BRUCKERT E，et al.Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia［J］.Circulation，2002，105（21）:2469-2475. [12] CHANG JT, STAFFA JA, Parks M, et al. Rhabdomyolysis with MHG-CoA reductase inhibitors and gemfibrozil combination therapy[J]. Pharmacoepidemiol Drug Saf, 2004,13(7):417-426. [13] ACCORD Study Group, GINSBERG HN, ELAM MR, et al. Effects of combination lipid therapy in type 2 diabetes mellitus[J]. N Engl J Med, 2010,362(17):1563-1574. [14] TAYLOR AJ, SULLENBERGER LE, LEE HJ, et al. Arterial Biology for Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind placebo-controlled study of extended-release niacin on Atherosclerosis progression in secondary prevention patients treated with statins[J]. Circulation, 2004,110(23):3512-3517. [15] DAVIDSON MH, STEIN EA, BAYS HE, et al. Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study[J]. Clin Ther, 2007,29(7):1354-1367. [16] AIM-HIGH Investigators, BODEN WE, PROBSTFIELD JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med, 2011,365(24):2255-2267.

[1]	SUN Jiaying, ZHOU Pengxiang, XIA Yu, YAN Ming, ZHOU Xinmei, WU Lingyan, TONG Yuling, ZHAO Yang, XU Zhijie. Interpretation of a Position Statement from an Italian Scientific Consortium: Medication Review and Deprescribing [J]. Chinese General Practice, 2025, 28(36): 4550-4557.
[2]	ZHENG Xiaomeng, ZHOU Xuan, SUN Yu, FAN Miao, JIN Yiyi, ZHU Suyan. Clinical Characteristics and Medication Patterns of Patients with Cardiometabolic Multimorbidity [J]. Chinese General Practice, 2025, 28(09): 1061-1064.
[3]	ZHU Suyan, ZHENG Xiaomeng, FAN Miao, CHEN Chunyan. Interpretation of the Screening Tool of Older Person's Potentially Inappropriate Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) Criteria (Version 3) [J]. Chinese General Practice, 2024, 27(33): 4097-4104.
[4]	XU Huijing, WU Shanyu, JIANG Jiawei, WU Yuanhong, WANG Xiaohui, GAO Ge, WANG Zhe, WANG Yuyu. Translation of the Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life and Its Validation in Elderly Patients with Polypharmacy [J]. Chinese General Practice, 2024, 27(05): 612-621.
[5]	ZENG Senxiang, YANG Rui, DENG Xun, YANG Ruitao, YANG Xiaoyan. Management Standards of Polypharmacy in Type 2 Diabetes Combined with Atherosclerotic Cardiovascular Diseases in the Elderly [J]. Chinese General Practice, 2024, 27(05): 597-603.
[6]	ZHONG Pingping, NAN Yayun, PENG Linlin, ZHOU Yuting, CHEN Qiong. A Bibliometrics Analysis of Polypharmacy in the Elderly from 2003 to 2022 [J]. Chinese General Practice, 2023, 26(35): 4404-4411.
[7]	XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403.
[8]	XU Man, AN Zhuoling, ZHANG Yuhui, MA Zhuo. Current Situation of Potentially Inappropriate Medication in Older Cancer Patients and Strategies to Address It [J]. Chinese General Practice, 2023, 26(35): 4382-4387.
[9]	WEI Lan, HUANG Yue, SONG Yanan, HOU Lihong, WANG Yani, PAN Dongchen, FEI Xiaolu. Investigation on Platform for Evaluation Management and Consultation Services of Polypharmacy among Older Patients Needs of Healthcare Professionals [J]. Chinese General Practice, 2023, 26(25): 3157-3162.
[10]	WEI Lan, HUANG Yue, SONG Yanan, HOU Lihong, WANG Yani, PAN Dongchen, FEI Xiaolu. Investigation on Platform for Evaluation Management and Consultation Services of Polypharmacy among Older Patients Needs of General Population [J]. Chinese General Practice, 2023, 26(25): 3163-3169.
[11]	CHEN Xiaomin, ZHANG Lina, LI Youjia. Characteristic of Polypharmacy in Older Adults with Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(10): 1271-1277.
[12]	YI Huijie, LIAO Xinyi, PI Mengyuan, XU liyue, ZHANG Chi, DONG Xiaosong, HAN Fang. Development of a New Remote Diagnosis and Treatment Model for Obstructive Sleep Apnea: a Non-inferiority Randomized Controlled Trial Protocol [J]. Chinese General Practice, 2023, 26(03): 380-385.
[13]	ZHANG Yili, HUANG Xinyi, QI Baoyu, SUN Chuanrui, WANG Xiaoyang, WEI Xu, XIE Yanming. Multimorbidity in Elderly Population: Challenges and Coping Strategies [J]. Chinese General Practice, 2022, 25(35): 4363-4368.
[14]	Chinese Medical Association Clinical Pharmacy Branch. Chinese Expert Consensus on Medication Safety in Polypharmacy in Type 2 Diabetics with Chronic Kidney Disease [J]. Chinese General Practice, 2022, 25(23): 2819-2835.
[15]	Yuanyuan XU, Zhijie XU, Yating NI, Xujian LIANG, Xueting HU, Zheming FANG, Yue ZHU, Lizheng FANG. Deprescribing for Older Adults in the Community: Recent Developments and Implications for China [J]. Chinese General Practice, 2022, 25(13): 1557-1563.